PMID- 26321711
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20220321
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 42
IP  - 8
DP  - 2015 Aug
TI  - [Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day 
      Introductory Period-The Japanese Style of Collaborative Drug Therapy 
      Management(J-CDTM)].
PG  - 967-72
AB  - Afatinib is a newly approved second-generation epidermal growth factor 
      receptor-tyrosine kinase inhibito r(EGFR-TKI). Afatinib has been shown to 
      prolongthe overall survival of patients with non-small cell lungcancer (NSCLC) 
      with EGFR mutations compared with the standard chemotherapy. However, Grade 3 or 
      4 toxicities, includingdiarrhea, rash, paronychia, and stomatitis, have been 
      observed more frequently in patients treated with afatinib than in those treated 
      with first-generation EGFR-TKIs. Accordingly, our institution developed an 
      afatinib clinical pathway (the afatinib pathway), which was designed by certified 
      nurses, medical physicians, and certified pharmacists, with the goal of reducing 
      the severity of diarrhea and rash that occur most frequently duringthe 28-day 
      introductory period of afatinib treatment. Between May and October 2014, afatinib 
      was administered accordingto the afatinib pathway to 14 patients with NSCLC and 
      EGFR mutations. Of these patients, only one (7.1%) experienced Grade 3 diarrhea. 
      No other patient experienced Grade 3 or 4 toxicity. The afatinib pathway was 
      effective in reducingthe severities of the diarrhea and rash duringthe 28-day 
      introductory period of the afatinib treatment. Our implementation of the afatinib 
      pathway could be considered the Japanese style of collaborative drugtherapy 
      management (J-CDTM).
FAU - Iwata, Kaori
AU  - Iwata K
AD  - Team for Making the Clinical Pathway of Afatinib, Osaka Prefectural Medical 
      Center for Respiratory and Allergic Diseases.
FAU - Ryota, Noriko
AU  - Ryota N
FAU - Hikita, Ami
AU  - Hikita A
FAU - Sando, Masumi
AU  - Sando M
FAU - Suzuki, Hidekazu
AU  - Suzuki H
FAU - Tamiya, Motohiro
AU  - Tamiya M
FAU - Azuma, Yuichiro
AU  - Azuma Y
FAU - Tani, Eriko
AU  - Tani E
FAU - Hamaguchi, Masanari
AU  - Hamaguchi M
FAU - Tanaka, Ayako
AU  - Tanaka A
FAU - Shiroyama, Takayuki
AU  - Shiroyama T
FAU - Morishita, Naoko
AU  - Morishita N
FAU - Okamoto, Norio
AU  - Okamoto N
FAU - Futagami, Sumiko
AU  - Futagami S
FAU - Hirashima, Tomonori
AU  - Hirashima T
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 41UD74L59M (Afatinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Afatinib
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Diarrhea/chemically induced
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Exanthema/chemically induced
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Medication Therapy Management
MH  - Middle Aged
MH  - Mutation
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2015/09/01 06:00
MHDA- 2015/09/19 06:00
CRDT- 2015/09/01 06:00
PHST- 2015/09/01 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2015 Aug;42(8):967-72.